Publicaciones
El conocimiento generado en IrsiCaixa se comparte con la comunidad científica a través de la publicación de artículos en revistas científicas de alto impacto.
Nitrogen positional scanning in tetramines active against HIV-1 as potential CXCR4 inhibitors.
P-glycoprotein (ABCB1) activity decreases raltegravir disposition in primary CD4+P-gphigh cells and correlates with HIV-1 viral load.
Management of bone mineral density in HIV-infected patients.
Removal of Dolutegravir by Hemodialysis in HIV-Infected Patients with End-Stage Renal Disease.
A human immune data-informed vaccine concept elicits strong and broad T-cell specificities associated with HIV-1 control in mice and macaques.
Increased ex vivo cell death of central memory CD4 T cells in treated HIV infected individuals with unsatisfactory immune recovery.
Second European Round Table on the Future Management of HIV: 10-11 October 2014, Barcelona, Spain.
Once-daily dolutegravir versus darunavir plus ritonavir for treatment-naive adults with HIV-1 infection (FLAMINGO): 96 week results from a randomised, open-label, phase 3b study.
[Resistance profile and genetic barrier of dolutegravir].
Primary resistance to integrase strand-transfer inhibitors in Europe.